<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="302">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05157217</url>
  </required_header>
  <id_info>
    <org_study_id>N-134-2020</org_study_id>
    <nct_id>NCT05157217</nct_id>
  </id_info>
  <brief_title>Impact of the Genetic Polymorphism on COVID-19 in Egypt</brief_title>
  <official_title>Impact of the Genetic Polymorphism on the Severity of COVID-19 Infection in Egyptian Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Misr International University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COVID-19 infection severity depends on many factors, including genetic factors. The SNPs&#xD;
      of ACE1, ACE2 and TMPRSS2; which have a big role in the viral entry to the cells, will be&#xD;
      tested and help establish a relationship between the genetic variation in these SNPs and the&#xD;
      severity of the COVID-19 symptoms. The aim of this study is to detect the association between&#xD;
      ACE1, ACE2 and TMPRSS2 gene polymorphism variants and occurrences of severe complications in&#xD;
      Egyptians patients with COVID-19 disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The world has been battling with the COVID-19 pandemic since the end of 2019, which is caused&#xD;
      by the highly contagious SARS-CoV-2 with over 25 million confirmed cases all around the&#xD;
      world. Although it has been the focus of many studies, this new pandemic is still an enigma&#xD;
      in many ways. The severity of the symptoms can vary from mild symptoms with flu-like symptoms&#xD;
      and self-limiting disease to severe respiratory symptoms that needs hospitalization and ICU&#xD;
      admission and can lead to death. Several factors have been speculated to affect the severity&#xD;
      of the COVID-19 infection including genetic factors. In this study, we will investigate the&#xD;
      variation in three different SNPs, one for the ACE2 gene which is the binding receptor for&#xD;
      the SARS-CoV-2 virus (rs908004, consequence: 3 Prime UTR Variant, Alleles: C&gt;G / C&gt;T), one&#xD;
      for the ACE (I/D) gene; which can in term affect the ACE2 receptor and the probability for&#xD;
      lung injury ( rs4343, Consequence: Synonymous Variant, Alleles: G&gt;A), and one for the TMPRSS2&#xD;
      gene; which is a transmembrane protease which activates the viral spike by priming it when it&#xD;
      is attached to the ACE2 receptor ( rs12329760, consequence: Missense Variant, Alleles: C&gt;T),&#xD;
      and conclude if they have any effect in the COVID-19 disease severity and need for&#xD;
      hospitalization and admission to the ICU. The aim is:&#xD;
&#xD;
        -  To detect the incidence of angiotensin-converting enzyme Insertion/Deletion (ACE I/D),&#xD;
           angiotensin-converting enzyme 2 (ACE2) and type 2 transmembrane serine protease&#xD;
           (TMPRSS2) gene polymorphisms in the Egyptian population.&#xD;
&#xD;
        -  To detect association between angiotensin-converting enzyme Insertion/Deletion (ACE I/D)&#xD;
           gene polymorphism variants and occurrences of severe complications in patients with&#xD;
           COVID-19 disease.&#xD;
&#xD;
        -  To detect association between angiotensin-converting enzyme 2 (ACE2) gene polymorphism&#xD;
           variants and occurrences of severe complications in patients with COVID-19 disease.&#xD;
&#xD;
        -  To detect association between type 2 transmembrane serine protease (TMPRSS2) gene&#xD;
           polymorphism variants and occurrences of severe complications in patients with COVID-19&#xD;
           disease.&#xD;
&#xD;
        -  To investigate the potential interaction between ACE (I/D), ACE2 and TMPRSS2 gene&#xD;
           polymorphisms and the occurrences of severe complications in patients with COVID-19&#xD;
           disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>ACE I/D gene polymorphism (rs4343)</measure>
    <time_frame>3 months</time_frame>
    <description>Genotypic and allele frequencies of the studied SNPS in both study groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Angiotensin-converting enzyme 2 (ACE2) gene polymorphism (rs908004)</measure>
    <time_frame>3 months</time_frame>
    <description>Genotypic and allele frequencies of the studied SNPS in both study groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Type 2 transmembrane serine protease (TMPRSS2) gene polymorphism (rs12329760)</measure>
    <time_frame>3 months</time_frame>
    <description>Genotypic and allele frequencies of the studied SNPS in both study groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Potential interaction between ACE (I/D), ACE2 and TMPRSS2 gene polymorphisms and the occurrences of severe complications in patients with COVID-19 disease.1</measure>
    <time_frame>3 months</time_frame>
    <description>Genotypic and allele frequencies of all studied SNPS in patients who suffered from serious respiratory complications that needed hospitalization or admission to the ICU</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">98</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>COVID-19 carriers who were infected with SARS-CoV-2 and healed without suffering from any respiratory complications or the need for hospitalization</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>COVID-19 patients who suffered from serious respiratory complications that needed hospitalization or admission to the ICU</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A baseline blood sample 3 ml on EDTA tube for genotyping of the studied alleles&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Egyptian patients who are either : infected with SARS-CoV-2 and healed without suffering&#xD;
        from any respiratory complications or the need for hospitalization Or infected with&#xD;
        SARS-CoV-2 who suffered from serious respiratory complications that needed hospitalization&#xD;
        or admission to the ICU.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Ø Positive nasal Swap for COVID-19 Infection. Ø Age of 18 years to 80 years. Ø Written&#xD;
        informed consent of the subject to participate in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Ø Patients with any prior respiratory problems such Asthma and COPD.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naglaa S Bazan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Khaled Farouk, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adel RA Abdallah, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Al-Azhar University in Cairo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abdelrahman A Abdelgawad, BScPharm</last_name>
    <role>Principal Investigator</role>
    <affiliation>Misr International University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neven MA Sarhan, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Misr International University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Raed SA Ismail, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Al-Azhar University in Cairo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed GL El-Ansary, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mona Schaalan, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Misr International University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Naglaa S Bazan, PhD</last_name>
    <phone>01005807504</phone>
    <phone_ext>002</phone_ext>
    <email>naglaabazan@cu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Abdelrahman A Abdelgawad, BScPharm</last_name>
    <phone>01119110322</phone>
    <phone_ext>002</phone_ext>
    <email>abdelrahman114549@miuegypt.edu.eg</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cairo University Hospitals</name>
      <address>
        <city>Cairo</city>
        <zip>11562</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Naglaa S Bazan, PhD</last_name>
      <phone>01005807504</phone>
      <phone_ext>002</phone_ext>
      <email>naglaabazan@cu.edu.eg</email>
    </contact>
    <contact_backup>
      <last_name>Khaled Farouk, MD</last_name>
      <phone>01223224570</phone>
      <phone_ext>002</phone_ext>
      <email>khaledfarouk.mdccm@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, Schiergens TS, Herrler G, Wu NH, Nitsche A, Müller MA, Drosten C, Pöhlmann S. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.</citation>
    <PMID>32142651</PMID>
  </results_reference>
  <results_reference>
    <citation>Zheng H, Cao JJ. Angiotensin-Converting Enzyme Gene Polymorphism and Severe Lung Injury in Patients with Coronavirus Disease 2019. Am J Pathol. 2020 Oct;190(10):2013-2017. doi: 10.1016/j.ajpath.2020.07.009. Epub 2020 Jul 29. Review.</citation>
    <PMID>32735889</PMID>
  </results_reference>
  <results_reference>
    <citation>Asselta R, Paraboschi EM, Mantovani A, Duga S. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. Aging (Albany NY). 2020 Jun 5;12(11):10087-10098. doi: 10.18632/aging.103415. Epub 2020 Jun 5.</citation>
    <PMID>32501810</PMID>
  </results_reference>
  <results_reference>
    <citation>Hou Y, Zhao J, Martin W, Kallianpur A, Chung MK, Jehi L, Sharifi N, Erzurum S, Eng C, Cheng F. New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. BMC Med. 2020 Jul 15;18(1):216. doi: 10.1186/s12916-020-01673-z.</citation>
    <PMID>32664879</PMID>
  </results_reference>
  <results_reference>
    <citation>Itoyama S, Keicho N, Quy T, Phi NC, Long HT, Ha LD, Ban VV, Ohashi J, Hijikata M, Matsushita I, Kawana A, Yanai H, Kirikae T, Kuratsuji T, Sasazuki T. ACE1 polymorphism and progression of SARS. Biochem Biophys Res Commun. 2004 Oct 22;323(3):1124-9.</citation>
    <PMID>15381116</PMID>
  </results_reference>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 11, 2021</study_first_submitted>
  <study_first_submitted_qc>December 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2021</study_first_posted>
  <last_update_submitted>December 11, 2021</last_update_submitted>
  <last_update_submitted_qc>December 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Naglaa Samir Ahmed Bazan</investigator_full_name>
    <investigator_title>Ass. Professor and Acting Head of Clinical Pharmacy Department - Cairo University Hospitals</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Genetic Polymorphism</keyword>
  <keyword>Pharmacogenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Study protocol</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

